T1	Participants 359 442	women with operable breast cancer with histologically positive axillary lymph nodes
T2	Participants 477 518	patients with a 68-month median follow-up
T3	Participants 563 582	172 receiving CMFVP
T4	Participants 594 615	186 women given L-PAM
